LQ-082

N/A

Report date: 2025/04/15 17:01:17

Base Information

Drug NameLQ-082
Drug Alias NameLQ-082LQ082
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionIntegrin alpha-4/beta-7 inhibitorsTumor necrosis factor superfamily member 15 inhibitorsInterleukin 23 Receptor inhibitors
TargetsIntegrin alpha-4/beta-7Tumor necrosis factor superfamily member 15Interleukin 23 Receptor
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCrohn DiseaseColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A